More recently, for the secondary prevention of hyperlipidemia, the Niemann–Pick transport inhibitor ezetimibe, and inhibitors of the proprotein convertase subtilisin/kexin type 9 (PCSK9) have become available and allow for even further reductions in LDL cholesterol in high-risk patients. This evidence concerns the gene PCSK9 and hyperlipidemia.